Save to Existing Project
Save to a New Project
Yeda R&D Co. Ltd
Abstract ID: 1433
Glaucoma is a common cause of blindness in industrialized countries and is the most frequent cause of irreversible blindness worldwide. Since raised intraocular pressure (IOP) has been implicated...
Glaucoma is a common cause of blindness in industrialized countries and is the most frequent cause of irreversible blindness worldwide. Since raised intraocular pressure (IOP) has been implicated as the major risk factor, the main goal of all glaucoma therapies is to reduce IOP sufficiently to prevent continuous irreversible retinal cell damage. All the existing medications have local and systemic side effects, from eye burning to breathing difficulties.
Therefore there is a clear need for a new generation of glaucoma drugs with a safer profile.
Researchers at Prof. Steve Karlish's lab developed novel derivatives of Digoxin that can be topically applied to the eyes. The current technology is based on derivatives of Digoxin, an inhibitor of the Na-K-ATPase pump, which is critical for the production of the eye fluids. The novel derivatives of Digoxin present higher selectivity towards the alpha2 isoform of the Na-K-ATPase pump that is more prevalent in the eye epithelium. Importantly, this molecular specificity offers a well-tolerated safety profile. Overall, this technology offers an effective reduction in ocular hypertension, the major risk factor in glaucoma, with diminished local side effects.
Alpha2-selective inhibitors effectively reduce IOP, and are therefore suitable for treating glaucoma and other ocular hypertension-associated diseases.
Please enquire quoting reference no. 1433 regarding licensing or codevelopment partnerships.
Last Updated May 2015